CTR20262412 Relugolix Castration-sensitive prostate cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Turn a newly registered trial into a decision-ready landscape. This focused report examines CTR20262412—瑞卢戈利片治疗激素敏感性晚期前列腺癌有效性和安全性的多中心Ⅲ期临床试验—using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, Drug & Asset MCP for mechanism and development context, and Company & Deal Intelligence MCP for sponsor background. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 20 July 2026; publication date: 20 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why CTR20262412 is a hot trial to watch

Castration-sensitive prostate cancer is increasingly segmented by mechanism, biomarker, treatment setting, geography and endpoint architecture. CTR20262412 is notable because it evaluates Relugolix in a Phase 3 design while 血清睾酮的持续去势率，定义为从第5周第1天（D29）至第25周第1天（D169）血清睾酮水平达到并维持去势水平，即≤50 ng/dL（1.7nmol/L）的累积概率。 serves as the main decision variable. The critical question is whether the protocol can convert its rationale into a clinically interpretable and operationally credible readout.

PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add development-status, target and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The phase label is only the starting point. Allocation is 非随机化, masking is 开放, and the intervention model is 单臂试验. Planned enrollment of 110 participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.

• Primary: 血清睾酮的持续去势率，定义为从第5周第1天（D29）至第25周第1天（D169）血清睾酮水平达到并维持去势水平，即≤50 ng/dL（1.7nmol/L）的累积概率。 (给药至临床试验结束)
• Secondary: 血清睾酮去势率[在第1周第4天（D4）、第2周第1天（D8）、第3周第1天（D15）睾酮抑制至≤50 ng/dL（1.7 nmol/L）的累积概率]。 (给药至临床试验结束)
• Secondary: 血清睾酮显著去势率[从第13周第1天（D85）至第25周第1天（D169）睾酮抑制至≤20ng/dL（0.7 nmol/L）的累积概率]。 (给药至临床试验结束)
• Secondary: 前列腺特异性抗原（PSA）应答率[第3周第1天（D15）PSA 较基线降低≥50%且在第5周第1天（D29）保持的患者比例]。 (给药至临床试验结束)
• Secondary: 至 PSA 进展时间；即发生下列情况的时间：①PSA 较基线水平下降：较最低点升高≥25%且绝对值升高≥2ng/mL，并需要≥3 周后再次检测 PSA 确认； (给药至临床试验结束)

Benchmark readouts in the surrounding field

• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of RDX-002 on Postprandial Triglycerides in Patients Discontinuing the Glucagon-like Peptide-1 (GLP-1) Agonists, Semaglutide, or Tirzepatide for the Treatment of Obesity (Phase 2): Incremental Postprandial Triglycerides (TG)(Mean) = 43.81 percent change (Standard Deviation, 92.373); Incremental Postprandial Triglycerides (TG)(Mean) = -51.91 percent change (Standard Deviation, 72.293)
• A Phase II Study to Evaluate the Delay in Ovulation Following Oral Levonorgestrel Plus Meloxicam Compared to Placebo in Obese But Normal Menstruating Women (Phase 2): Interval From First Dose to Evidence of Ovulation.(Mean) = 2.67 Number of days (Standard Deviation, 1.53); Interval From First Dose to Evidence of Ovulation.(Mean) = 4.0 Number of days (Standard Deviation, 0)
• A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight (Phase 2): Percent Change From Baseline in Body Weight at Week 48(Least Squares Mean) = -0.4 percent change (Standard Error, 0.91); Percent Change From Baseline in Body Weight at Week 48(Least Squares Mean) = -9.4 percent change (Standard Error, 1.60)

These indexed results are contextual benchmarks, not direct head-to-head evidence. Population, treatment line, endpoint definitions, follow-up and analysis sets may differ. Their value is to clarify the type and magnitude of evidence already visible in the competitive landscape.

Build a living trial monitor: connect to PatSnap MCP Servers and track status changes, endpoint revisions, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Relugolix (Approved; GnRHR)

Company & Deal Intelligence context: Hangzhou CONBA Pharmaceutical Co. Ltd. — China

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
• Sequencing evidence: comparative data after the most relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter probability of success before a headline data release.

Bottom line

CTR20262412 is a focused lens on Castration-sensitive prostate cancer development. Its value will be determined by whether Relugolix can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from indexed benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.